Chat with us, powered by LiveChat Discuss | Lhasa Limited

Discuss

Explore topical blogs discussing chemical safety assessment.

Lhasa Limited shortlisted for the Lush Prize 2026 for science, advancing non-animal approaches to DART through human-relevant, in silico toxicology.

We’ve been shortlisted for the Lush Prize 2026 – Science

We’re delighted to share that Lhasa Limited has been shortlisted for the Lush Prize 2026 in the Science category, an award recognising research teams whose work is most likely to lead to practical, regulator-accepted non-animal testing approaches. The Lush Prize exists to accelerate the transition to 21st-century toxicology, with the ultimate goal of ending the […]

We’ve been shortlisted for the Lush Prize 2026 – Science Read More »

Lhasa publication awards for chemical safety achievement

2025 Lhasa Publication Awards: The leading research in chemical safety

Just before the holiday period, our community voted on the most impactful scientific papers of the year authored by industry and regulatory experts and co-authored with Lhasa Limited. These awards recognise the work driving progress in toxicology and chemistry. They highlight the vital collaborative efforts between our scientists and industry partners, helping to shape the

2025 Lhasa Publication Awards: The leading research in chemical safety Read More »

Lhasa Limited 2025 Wrap-up

Lhasa 2025 wrap-up: New milestones in regulatory science and safety assessment

Curious to find out what we’ve been up to in 2025? This year, we have driven advancements in regulatory science, delivered innovation in chemical safety software, and built stronger global collaborations. Watch our 2025 wrap-up Click the button above to jump to the video, or read all about our milestones below. One of our standout

Lhasa 2025 wrap-up: New milestones in regulatory science and safety assessment Read More »

Lhasa attended - E&Ls Europe 2025: Building defensible justifications under ICH Q3E

E&Ls Europe 2025: Building defensible justifications under ICH Q3E

Insights on ICH Q3E, Extractables & Leachable (E&L) and risk assessment submissions Interpreting grey areas in the draft ICH Q3E guideline Earlier this month, the Lhasa Limited team, alongside Dr Lance Molnar, Head of Non-Clinical Operations and Risk Assessments at Viatris, and Dr Patricia Parris, Toxicology Impurity Risk Management at Pfizer, attended the Smithers E&L

E&Ls Europe 2025: Building defensible justifications under ICH Q3E Read More »

ICH S1B(R1) live Q&A webinar

Insights from the experts: Key takeaways from the ICH S1B(R1) live Q&A

Following our recent Lhasa Limited hosted webinar, ICH S1B(R1): industry and regulatory best practice for confident carcinogenicity assessment, attendees had the rare opportunity to engage directly with experts who helped shape the ICH S1B(R1) Addendum. The ICH S1B(R1) Addendum is a globally recognised guideline that introduces a weight-of-evidence (WoE) approach to assessing the carcinogenic potential

Insights from the experts: Key takeaways from the ICH S1B(R1) live Q&A Read More »

Discover how Vitic can assist with providing expert toxicity data for the ICH M7 guidelines on mutagenic impurities for an efficient workflow.

Driving efficient early-stage ICH M7 classification through reliable mutagenic and carcinogenic data

In this latest blog, we will define the difference between certainty and uncertainty in the ICH M7 guideline for mutagenic impurities. Delving into the power of existing experimental data, we’ll address how Vitic’s expert toxicity database can accelerate the workflow of Classes 1, 2 and 5 in mutagenicity risk assessments. To Toxicologists, the ICH M7

Driving efficient early-stage ICH M7 classification through reliable mutagenic and carcinogenic data Read More »

KAptis Weight of Evidence ICH S1b(r1)

Applying ICH S1B(R1) in 5 steps: Carcinogenicity assessment made simple with Kaptis

Carcinogenicity assessment is a critical step in drug development. Teams must balance regulatory compliance, development timelines, and ethical testing, often with incomplete datasets. The revised ICH S1B(R1) guideline introduces a weight-of-evidence (WoE) approach that provides a more structured, efficient, and human-relevant path forward. By applying this framework, organisations can benefit from: $2 – 4M cost

Applying ICH S1B(R1) in 5 steps: Carcinogenicity assessment made simple with Kaptis Read More »

Lhasa Limited attended EUROTOX 2025

EUROTOX 2025: Highlights from Athens

Insights on ICH S1B(R1), genotoxicity and best practices in toxicology. The 59th Congress of the European Societies of Toxicology (EUROTOX) brought the global toxicology community together in Athens under the theme “Toxicology addresses society’s real-life risks for sustainable health and well-being.” Discussions throughout the congress reflected a shared ambition: applying science and innovation to deliver

EUROTOX 2025: Highlights from Athens Read More »

Ready to discover the power of in silico chemical structure search using Vitic? Here's everything you need to know about toxicity database searching

The power of in silico structure searching to achieve data driven decision making with confidence

In this blog, we explore the value of chemical structure search functionality in Vitic. Structure searching directs our members toward toxicity insights that can help guide their risk and safety assessments. We’ll discuss how chemical structure searches are conducted and the value that a toxicity database like Vitic can bring to decision making. A key

The power of in silico structure searching to achieve data driven decision making with confidence Read More »

ICH Q3E - what the new guidelines mean for you

ICH Q3E – what the new E&L draft guideline means for you

The release of the ICH Q3E for public consultation marks a significant milestone for the pharmaceutical industry. It sets out a harmonised, risk-based framework for the assessment and control of organic impurities that migrate from packaging or manufacturing components into a final drug. For years, organisations navigated a complex web of regional expectations for extractables

ICH Q3E – what the new E&L draft guideline means for you Read More »